Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Up 1.9 %

Shares of NASDAQ:AKTX opened at $3.22 on Monday. Akari Therapeutics has a 1-year low of $1.08 and a 1-year high of $4.40. The firm has a fifty day moving average price of $3.60 and a 200 day moving average price of $2.59.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.